Olomorasib + Pembrolizumab for Non-Small Cell Lung Cancer

This trial tests a new treatment combination for individuals with advanced non-small cell lung cancer (NSCLC) that cannot be cured. The combination includes olomorasib, a potential new drug, and pembrolizumab, an immunotherapy drug, to determine if they can extend the time patients live without cancer progression. The study also evaluates the treatment's effectiveness in shrinking tumors and monitors any side effects. Participants with a specific gene mutation (KRAS G12C) and a protein score (PD-L1 between 1% and 49%) may be suitable candidates. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Earlier studies have shown that the combination of olomorasib and pembrolizumab is safe for patients with advanced non-small cell lung cancer (NSCLC) who have a specific genetic change called KRAS G12C. Research suggests that patients generally tolerate this treatment well. Those who tried it reported manageable side effects. While some side effects occurred, they were not severe for most patients. The FDA has granted this combination a Breakthrough Therapy Designation, indicating its promise in treating this type of cancer.¹²³⁴⁵

Researchers are excited about the combination of Olomorasib and Pembrolizumab for treating non-small cell lung cancer (NSCLC) because it targets a specific mutation known as KRAS G12C. This is significant because most current treatments don't specifically address this mutation, which is found in a subset of NSCLC patients. Olomorasib works by directly inhibiting the KRAS G12C mutation, while Pembrolizumab is an immunotherapy that helps the body's immune system attack cancer cells. By combining these two mechanisms, the treatment offers a promising new approach that could potentially improve outcomes for patients who have limited options with existing therapies.

Research has shown that combining olomorasib with pembrolizumab may effectively treat advanced non-small cell lung cancer (NSCLC) with a specific KRAS G12C mutation. In this trial, participants with locally advanced or metastatic NSCLC will receive this combination. Studies have found that up to 77% of patients experienced tumor shrinkage with this treatment. This combination is noted for its strong tumor-fighting ability and generally manageable safety profile. These findings suggest that this treatment could help slow cancer progression and improve patient outcomes.¹²³⁴⁵